在 HIV-1 感染早期，阿昔洛韦对单纯疱疹病毒 2 型血清阳性者 HIV-1 设定点的影响。
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
机构信息
Department of Medicine, Schools of Medicine and Public Health, University of Washington, 325 Ninth Avenue, Seattle, WA 98104, USA.
出版信息
J Infect Dis. 2010 Sep 1;202(5):734-8. doi: 10.1086/655662.
Abstract
We evaluated whether acyclovir suppression during human immunodeficiency virus type 1 (HIV-1) acquisition reduces HIV-1 set point, increases CD4 cell counts, and selects reverse-transcriptase mutations among 76 HIV-1 seroconverters identified in a placebo-controlled trial of twice-daily acyclovir (400 mg) for the prevention of HIV acquisition in herpes simplex virus type 2 (HSV-2)-seropositive persons (HIV Prevention Trials Network study 039). We found no significant difference in plasma HIV-1 RNA levels (P =.30) or CD4 cell counts (P =.85) between the acyclovir and placebo recipients. V75I and other mutations in HIV-1 reverse transcriptase reported from in vitro acyclovir studies were not observed. In conclusion, acyclovir suppression during HIV-1 seroconversion and the subsequent 6 months does not affect HIV-1 set point.
摘要
我们评估了在人类免疫缺陷病毒 1 型（HIV-1）获得期间抑制阿昔洛韦是否会降低 HIV-1 定殖水平，增加 CD4 细胞计数，并在疱疹单纯病毒 2 型（HSV-2）血清阳性者中接受每日两次阿昔洛韦（400mg）预防 HIV 获得的安慰剂对照试验中识别的 76 例 HIV-1 血清转换者中选择逆转录酶突变（HIV 预防试验网络研究 039）。我们发现阿昔洛韦和安慰剂组之间的血浆 HIV-1 RNA 水平（P =.30）或 CD4 细胞计数（P =.85）没有显著差异。在体外阿昔洛韦研究中报告的 HIV-1 逆转录酶中的 V75I 和其他突变未观察到。总之，HIV-1 血清转换期间和随后的 6 个月内抑制阿昔洛韦不会影响 HIV-1 定殖水平。
相似文献
1
Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
J Infect Dis. 2010 Sep 1;202(5):734-8. doi: 10.1086/655662.
2
High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.
3
Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
J Clin Microbiol. 2010 Oct;48(10):3496-503. doi: 10.1128/JCM.01263-10. Epub 2010 Aug 11.
4
The effect of valacyclovir on HIV and HSV-2 in HIV-infected persons on antiretroviral therapy with previously unrecognised HSV-2.
Int J STD AIDS. 2015 Jul;26(8):574-81. doi: 10.1177/0956462414546504. Epub 2014 Aug 21.
5
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.
Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.
6
Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa.
AIDS. 2009 Feb 20;23(4):461-9. doi: 10.1097/QAD.0b013e32831db217.
7
Herpes simplex virus type 2 suppressive therapy with acyclovir or valacyclovir does not select for specific HIV-1 resistance in HIV-1/HSV-2 dually infected persons.
J Infect Dis. 2011 Jan 1;203(1):117-21. doi: 10.1093/infdis/jiq013.
8
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.
9
A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
Sex Transm Infect. 2008 Dec;84(7):548-53. doi: 10.1136/sti.2008.031153. Epub 2008 Aug 6.
10
Reduction of HIV-1 RNA levels with therapy to suppress herpes simplex virus.
N Engl J Med. 2007 Feb 22;356(8):790-9. doi: 10.1056/NEJMoa062607.
引用本文的文献
1
Does suppressive antiviral therapy for herpes simplex virus prevent transmission in an HIV-positive population? A systematic review.
Can Commun Dis Rep. 2016 Feb 4;42(2):37-44. doi: 10.14745/ccdr.v42i02a03.
2
Partners in Crime: The Role of CMV in Immune Dysregulation and Clinical Outcome During HIV Infection.
Curr HIV/AIDS Rep. 2016 Feb;13(1):10-9. doi: 10.1007/s11904-016-0297-9.
3
The Role of Sexually Transmitted Infections in HIV-1 Progression: A Comprehensive Review of the Literature.
J Sex Transm Dis. 2013;2013:176459. doi: 10.1155/2013/176459. Epub 2013 Jun 24.
4
Integrating prevention interventions for people living with HIV into care and treatment programs: a systematic review of the evidence.
J Acquir Immune Defic Syndr. 2015 Apr 15;68 Suppl 3(0 3):S286-96. doi: 10.1097/QAI.0000000000000520.
5
The Sordid Affair Between Human Herpesvirus and HIV.
J Infect Dis. 2015 Sep 15;212(6):845-52. doi: 10.1093/infdis/jiv148. Epub 2015 Mar 6.
6
Valacyclovir Decreases Plasma HIV-1 RNA in HSV-2 Seronegative Individuals: A Randomized Placebo-Controlled Crossover Trial.
Clin Infect Dis. 2015 Jun 1;60(11):1708-14. doi: 10.1093/cid/civ172. Epub 2015 Mar 3.
7
High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
J Acquir Immune Defic Syndr. 2013 Jun 1;63(2):201-8. doi: 10.1097/QAI.0b013e3182928eea.
8
Consistent inhibition of HIV-1 replication in CD4+ T cells by acyclovir without detection of human herpesviruses.
J Virol. 2011 May;85(9):4618-22. doi: 10.1128/JVI.02423-10. Epub 2011 Feb 16.
本文引用的文献
1
Clinical and virologic efficacy of herpes simplex virus type 2 suppression by acyclovir in a multicontinent clinical trial.
J Infect Dis. 2010 Apr 15;201(8):1164-8. doi: 10.1086/651381.
2
Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.
3
Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
AIDS. 2010 Jan 16;24(2):319-23. doi: 10.1097/QAD.0b013e32833424e5.
4
Mechanisms associated with HIV-1 resistance to acyclovir by the V75I mutation in reverse transcriptase.
J Biol Chem. 2009 Aug 7;284(32):21496-504. doi: 10.1074/jbc.M109.024026. Epub 2009 Jun 9.
5
The antiherpetic drug acyclovir inhibits HIV replication and selects the V75I reverse transcriptase multidrug resistance mutation.
J Biol Chem. 2008 Nov 14;283(46):31289-93. doi: 10.1074/jbc.C800188200. Epub 2008 Sep 24.
6
Acyclovir is activated into a HIV-1 reverse transcriptase inhibitor in herpesvirus-infected human tissues.
Cell Host Microbe. 2008 Sep 11;4(3):260-270. doi: 10.1016/j.chom.2008.07.008.
7
Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.
Lancet. 2008 Jun 21;371(9630):2109-19. doi: 10.1016/S0140-6736(08)60920-4.
8
HIV-1/HSV-2 co-infected adults in early HIV-1 infection have elevated CD4+ T cell counts.
PLoS One. 2007 Oct 24;2(10):e1080. doi: 10.1371/journal.pone.0001080.
9
Herpes simplex virus type 2 infection does not influence viral dynamics during early HIV-1 infection.
J Infect Dis. 2007 May 1;195(9):1270-7. doi: 10.1086/513568. Epub 2007 Mar 15.
10
Epidemiology of herpes simplex virus type 2 infection in the developing world.
Herpes. 2004 Apr;11 Suppl 1:24A-35A.
Zotero 插件